You are here: Industry Insights > AstraZeneca

News List

Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 worldpharmanews
March 29, 2017
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present the strength and depth of its translational science at the American Association for Cancer Research (AACR) Annual Meeting in Washington DC, US, 1-5 April 20
AstraZeneca's lung cancer therapy Tagrisso approved in China firstwordpharma
March 28, 2017
AstraZeneca announced Monday that the China Food and Drug Administration (CFDA) approved Tagrisso (osimertinib) for the treatment of adults with locally-advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (NSCLC).
AstraZeneca study shows SGLT-2 inhibitors significantly reduced hospitalizations for heart failure a cphi-online
March 22, 2017
Landmark real-world evidence from an international study of more than 300,000 patients with type-2 diabetes showed treatment with SGLT-2 inhibitors reduced risk of hospitalization for heart failure by 39% and all-cause mortality by 51%.
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabete worldpharmanews
March 01, 2017
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
AstraZeneca’s hyperkalaemia treatment rebounds with European recommendation pharmafile
February 27, 2017
AstraZeneca have received some positive news on its hyperkalaemia drug, ZS-9, as it received a recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the EMA.
AstraZeneca Phase III breast cancer trial met primary endpoint europeanpharmaceuticalreview
February 24, 2017
AstraZeneca announced positive results from its Phase III trial comparing Lynparza (olaparib) tablets to physician’s choice of a standard of care chemotherapy, in the treatment of patients with HER2-negative metastatic breast cancer, harbouring germline B
AstraZeneca and TerSera sign agreement to commercialise Zoladex in US and Canada pharmaceutical-technology
February 23, 2017
UK-based AstraZeneca has entered an agreement to sell the commercial rights for Zoladex (goserelin acetate implant) in the US and Canadian markets to pharmaceutical company TerSera Therapeutics.
AstraZeneca’s Lynparza hits breast cancer trial targets pharmatimes
February 21, 2017
A late-stage study of AstraZeneca's PARP inhibitor Lynparza in patients with HER2-negative metastatic breast cancer who also carry BRCA1 or BRCA2 mutations has its primary target in boosting progression-free survival (PFS).
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada worldpharmanews
February 21, 2017
AstraZeneca today announced that it has entered into an agreement with TerSera Therapeutics LLC (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada.
Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasi worldpharmanews
February 20, 2017
AstraZeneca's partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page